Who makes [14C]-CC-92480?

[14C]-CC-92480 is developed by Celgene.

Last reviewed 2026-04-19 · How we verify

[14C]-CC-92480

Celgene · Phase 1 active Small molecule

([14C]-CC-92480) is a compound developed by Celgene with no current FDA approval or clinical trials. Its mechanism of action and potential therapeutic uses are not yet fully characterized.

At a glance

Generic name	[14C]-CC-92480
Sponsor	Celgene
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-CC-92480 CI brief — competitive landscape report
[14C]-CC-92480 updates RSS · CI watch RSS
Celgene portfolio CI